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Background: Between 2010 and 2016, the proportion of children 12–23 months of age who received full im-
munization in Malawi decreased from 81% to 76%. Most studies on immunization have mainly focused on the
risk factors of vaccination coverage while data on dropouts and equity gaps is very scanty. Thus the aim of the
present study was to describe the trend in immunization coverage, dropout rates and effective immunization
coverage (EIC) among children ages 12–23 months in Malawi.
Methods: Secondary analyses of the cross-sectional data obtained from the three waves of the Demographic
and Health Surveys (2004, 2010 and 2015–16) were conducted. Using bottleneck analysis, outputs were gener-
ated based on service coverage, demand/equity (service utilization) and quality (full immunization). The World
Health Organization benchmarks were used to assess gaps in the immunization coverage indicators.
Results: The coverage was >90.0% in most of the antigens while full immunization status was estimated
at 65%, 84% and 73% in 2004, 2010 and 2015, respectively. The highest coverage was observed in Bacillus
Calmette–Guérin (BCG) and lowest in oral polio vaccine 1 (OPV1). OPV1 coverage was <90% in the 2004 cohort
year, while pentavalent 3 (Penta3) and measles-containing vaccine 1 (MCV1) coverages were <90% in 2004.
Dropout rates of Penta3 and MCV1 were significantly >10% in 2004. The logistic regression analyses showed
that children were significantly less likely to be immunized with Penta3 and MCV1 in all cohort years compared
with Penta1.
Conclusions: Although immunization coverage was in line with the national and district targets for various
antigens, full vaccination coverage (FVC) is still lagging behind. Furthermore, the dropout rates for Penta3 and
MCV1 showed upside U-shaped patterns. Thus health education, supervision and orientation of service providers
are urgently needed to address disparities that are existing in FVC.
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Background
Since the 20th century, immunization has been an effective tool
for controlling and eradicating life-threatening infectious dis-
eases.1 Every year, immunization prevents about 2–3million child
deaths.2 The global efforts to use immunization as a public health
intervention began when the World Health Organization (WHO)
launched the Expanded Programme on Immunization (EPI) in
1974, where six vaccines (diphtheria, whooping cough, tetanus,
measles, poliomyelitis and tuberculosis) were recommended for
children 0–24 months of age through routine infant immuniza-
tion.3 The original six recommended vaccines have been adopted
in many countries and new antigens have now been added into
the EPI.4 Despite the fact that immunization coverage has shown
significant improvements over the last 2 decades, the coverage
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Figure 1. Number of antigens introduced in the EPI schedule since 1979.
has remained stagnant at 86%, with no substantial changes over
recent years.2 To benefit from the direct and indirect effects of
immunization, the WHO came up with the Global Vaccine Action
Plan (GVAP), which set country targets of 90% coverage for all
antigens at the national level and at least 80% coverage for all
antigens in 80% of districts by the year 2020.5
In 1979, the Malawi EPI was officially launched and began
to administer vaccines against six diseases: a dose of Bacillus
Calmette–Guérin (BCG) vaccine against tuberculosis (TB); three
doses of diphtheria, tetanus and pertussis (DPT) vaccine against
diphtheria, tetanus and pertussis; at least three doses of oral polio
vaccine (OPV) against polio; and one dose of measles-containing
vaccine (MCV) against measles.6 However, it was reported that
only smallpox vaccinations were administered on a large scale
while antigens such as BCG and DPT were delivered in a few
health facilities in Malawi in the early 1970s.7 In the year 2012,
the Malawi government substituted the DPT vaccine with a pen-
tavalent vaccine that protects against DPT, hepatitis B virus (HBV)
and Haemophilus influenzae type b (Hib) in its EPI.8 Addition-
ally, in November 2011 and October 2012, the government of
Malawi introduced other new vaccines into its EPI: the pneumo-
coccal conjugate vaccine (PCV13) against bacterial pneumonia
and the monovalent human rotavirus vaccine (RV1) against se-
vere diarrhoea caused by rotavirus.9 In 2015 the Malawi gov-
ernment introduced a measles second dose, while in 2016 the
trivalent oral polio vaccine (tOPV) was switched to the bivalent
oral polio vaccine (bOPV). Similarly, the tetanus toxoid (TT) vac-
cine was switched to a tetanus–diphtheria (Td) vaccine, PCV13
was switched from one dose to four doses and the measles–
rubella (MR) vaccine was introduced. Additionally, in 2018–2019
the Malawi EPI planned to switch the bOPV to an inactivated po-
lio vaccine (IPV) and human papilloma vaccine (HPV) was intro-
duced for girls ≥10 y of age.10 Recently, in May 2019, the Malawi
government introduced the malaria vaccine (MV), also known as
RTS,S/AS01, into its EPI.11 Figure 1 displays the number of anti-
gens introduced in Malawi’s EPI schedule from 1979 to 2019.
TheMalawi EPI recommends that the BCG and polio 0 vaccines
should be given at birth or within the first 14 days after birth, the
Penta, PCV, RV and OPV should be given at approximately 6, 10
and 14 weeks of age. The MCV is recommended to be adminis-
tered as soonas the child reaches 9months of age.12 Additionally,
the TT vaccine is scheduled to be provided to pregnant women
at first contact. Table 1 presents the EPI schedule followed in
Malawi. Obstacles to reaching every child with the full comple-
ment of vaccines have been identified in some settings. These
factors include maternal education, distance to health facilities,
inadequate vaccines, poorly trained and motivated human re-
sources and poor quality of services.13 Studies from Malawi on
vaccination have reported that women’s low education, having
one or no antenatal visits, having no immunization card, having
an immunization card but not seen, residing in poor households,
having a large number of children and living in the central region
were themost significant factors associatedwith decreased odds
of achieving vaccination coverage and complete vaccination.7,14
Furthermore, other studies have cited that vaccines being out of
stock at the health facility level is a reason for no vaccination.15
Most of these studies have mainly focused on whether the child
has received full, under- or non-vaccination coverage.
Worldwide, about 85%of infants (116million infants) received
a DTP3 and one dose of MCV by the end of 2019, thus protect-
ing them against infectious diseases that can cause serious ill-
ness and disability. Meanwhile, 123 countries were reported to
have reached at least 90% coverage of DTP3.2 Similarly, the EPI
in Malawi has managed to sustain a high coverage of immu-
nization >80% of various antigens for several years. However,
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Table 1. Schedule of the Malawi EPI
Vaccine Description and number of antigens Schedule Comments
Primary infant and adolescent vaccination schedule
BCG Bacillus Calmette–Guérin (dose) At birth or first contact
OPV0 Oral polio vaccine 0 (dose) At birth to 2 weeks
Rotavirus Rotavirus vaccine (two doses) 6 and 10 weeks
Pentavalent Diphtheria and tetanus and pertussis and Haemophilus
influenzae and hepatitis B (three doses)
6, 10 and 14 weeks
OPV Oral polio vaccine (three doses) 6, 10 and 14 weeks
Pneumo_conj Pneumococcal conjugate vaccine (three doses) 6, 10 and 14 weeks
MV Malaria vaccine/RTS,S/AS01 (four doses) 5, 6, 7 and 22 months
Measles Measles vaccine (two doses) 9 and 15 months
MR Measles and rubella vaccine (two doses) 9 and 15 months From July 2017
HPV Human papillomavirus vaccine (two doses) 10 y Girls ages 9–14 y
Adult vaccination schedule
TT Tetanus toxoid vaccine First contact; +1 and +6 months;
+1 and +1 y
Pregnant women
children from 81% in 2010 to 76% in 2016.9 In Malawi, rou-
tine data on immunization are collected using two national rou-
tine administrative tools, the official WHO/United Nation Chil-
dren’s Fund (UNICEF) Joint Reporting Form (JRF) and the District
Vaccination Data Management Tool (DVDMT). Unfortunately, due
to data quality issues, these databases usually report inconsis-
tent coverage that is abnormally high as well as high dropout
rates. Even though the routine reports provide information on im-
munization coverage, information may be inaccurate and mis-
leading. Data quality plays a fundamental role in the success or
failure of an immunization programme and poor quality immu-
nization data threatens to undermine national and international
investments.16
InMalawi, theMalawi Demographic and Health Survey (MDHS)
focuses mainly on immunization coverage and completeness
of immunization. However, immunization dropouts are not re-
ported. The dropout rate is of great importance, as it indicates
whether there is an access problem for parents, i.e. whether they
have difficulty in getting to the immunization services for sub-
sequent doses or whether there is a problem for parents in utiliz-
ing the health services.17 Therefore coverage surveys can validate
routine reports and provide additional information on immuniza-
tion and identify strategies to improve immunization activities.
Accordingly, we aimed to describe the trend in immunization cov-
erage, dropouts, equity gaps and full vaccination coverage (FVC),
also known as effective immunization coverage, among children
12–23 months of age in Malawi.
Methods
Study setting
Malawi is part of sub-Saharan Africa, which is located in the
southeastern part of the continent. It is bordered to the north and
northeast by the United Republic of Tanzania; to the east, south
and southwest by the People’s Republic of Mozambique; and to
the west and northwest by the Republic of Zambia.8,18,19 Malawi
is one of the poorest countries in the world, with a gross national
income per capita of US$320 and about 85% of the population
live in rural areas.20 The economy of Malawi is based primarily on
agriculture, which accounts for 30% of the gross domestic prod-
uct.21 Healthcare services in Malawi are provided through both
the public and private sectors.22 The public sector includes all fa-
cilities under the Ministry of Health (MoH), Ministry of Local Gov-
ernment and Rural Development, Ministry of Forestry, the police,
the prisons and the army. The private sector consists of private
for-profit and private not-for-profit providers, mainly the Chris-
tian Association of Malawi (CHAM).10,22 The public sector provides
services free of charge while the private sector charges user fees
for its services. There are currently 977 health facilities in Malawi
comprising 113 hospitals, 466 health centres, 48 dispensaries,
327 clinics and 23 health posts. These health facilities are man-
aged by the government (n=472), CHAM (n=163), private orga-
nizations (n=283) and non-governmental organizations (n=58).
All these institutions provide immunization services in Malawi.5 In
the last 2 decades Malawi has seen a 30% decrease in mortality
rates in children<5 y of age, from 190 deaths per 1000 live births
to 133 per 1000 live births. It was reported that this decline was
due in part to neonatal mortality rates that decreased 36%, from
42 per 1000 live births to 27 per 1000 live births.23 The causes of
mortality in children <5 y of age in Malawi include malaria, di-
arrhoea and acute lower respiratory tract infection; all of these
conditions are preventable and have vaccines. The prevalence of
malaria, diarrhoea and pneumonia were reported at 24%, 22%
and 5%, respectively.9,24
Data sources
The current study analysed data obtained from the three waves
of the MDHS conducted in 2004, 2010 and 2015–2016. Details
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elsewhere.8,9,25 In brief, the surveys employed two-stage sam-
pling designed to produce nationally representative samples. The
surveys utilized sampling frames from the Malawi Population
and Housing Census (MPHC) conducted in 1998 and 2008. The
first stage selected 850, 849 and 522 clusters, known as stan-
dard enumeration areas (SEAs), proportional to the population in
2015–2016, 2010 and 2004, respectively. The second stage in-
volved selection of 27 516, 27 307 and 15 041 households from
the SEAs with an equal probability systematic selection in 2015–
2016, 2010 and 2004, respectively.
Data collection
The primary objective of the MDHS is to provide up-to-date es-
timates of basic demographic and health indicators. The sur-
veys provide a comprehensive overview of population, maternal
and child health issues in Malawi. Specifically, one of the ob-
jectives these surveys achieved was the collection of data on
the key aspects of family health, such as immunization cover-
age among children. Respondents were asked to show a health
passport or any other document where vaccines were written
down. If the respondents could not show a health or immu-
nization card, they were then asked to recall any vaccinations
ever received to prevent them from getting diseases, including
vaccinations received in health campaigns or immunization or
child health days. In particular, respondents were asked to re-
port whether the individual received BCG, polio, pentavalent, ro-
tavirus, pneumococcal and measles vaccines. Regarding polio,
pentavalent, rotavirus and pneumococcal vaccines, respondents
were further asked to report the number of times the individual
received each specific vaccine.8,9,25 In the selected households—
11698 in 2004, 23 020 in 2010 and24562 in 2015—womenwere
interviewed, representing 97.7%, 96.9% and 95.7%, respectively.
As recommended by the WHO,9 the present study included chil-
dren 12–23months of age. Thus the final samples analysed were
2211, 3741 and 3225 children in 2004, 2010 and 2015–2016,
respectively.
Inclusion criteria
All children 12–23 months of age prior to each survey, living with
their guardians and with information on immunization were in-
cluded in this study.
Bottleneck analysis (BNA) and framework
BNA is an approach based on the Monitoring of Results for Equity
System (MoRES) for planning equity-focused interventions and
identifying gaps in their uptake.26 The MoRES was developed in
2010 as part of UNICEF’s refocus on equity to ensure that UNICEF
is as effective as possible in the protection and promotion of chil-
dren’s rights.27 The BNA framework is premised on the notion that
effective coverage of services is influenced by fourmain domains:
supply, demand, quality and environment. Supply determinants
of services are predominantly controlled by the healthcare
delivery system and have three important components: com-
modities, human resources and geographic access. Demand de-
terminants of services are predominantly controlled by the com-
munity and have two important components known as initial
utilization and continuous utilization of services. Quality determi-
nants of services are predominantly controlled by the healthcare
delivery system and relate to the services being able to meet the
quality standards set within national guidelines. Lastly, environ-
mental influencers of services are thought to occur across all as-
pects of the programmeand include policy and regulatory frame-
works, management, coordination and sociocultural as well as
economic-related factors.13 However, in this studywe focused on
the demand and quality determinants of services since the DHS
does not have data on supply.
Variables and operational definitions
The following variables were included to describe the immu-
nization coverage, dropout and equity gaps among children 12–
23 months of age in Malawi. Immunization coverage was de-
fined as the proportion of children 12–23 months of age who re-
ceived the recommended EPI vaccine antigens compared with
the total number of infants who survived in the given target
population. Partially immunized children were those ages 12–
23 months who missed one or more of the scheduled prescribed
vaccines considered to protect themagainst vaccine-preventable
diseases. Unimmunized children were those who had not re-
ceived any of the scheduled EPI vaccinations. Dropout rate was
defined as the proportion of vaccination recipients who had be-
gun their schedules but did not complete them. The dropout
rate was calculated by comparing the number of infants who
were initiated in the vaccination schedule vs those who com-
pleted it. Two domains are habitually used to calculate the
dropout rate. These measures are the Penta vaccine and MCV1.
Specifically, the DPT dropout rate was calculated by dividing the
number of children 12–23 months of age who received DPT1
minus the number of children 12–23 months of age who re-
ceived DPT3 by the number of children 12–23 months of age
who received DPT1 (i.e. [Penta1−Penta3]/Penta1×100%). It can
also be calculated as the children ages 12–23 months who re-
ceived Penta1 and MCV1 divide by those who received Penta1
(i.e. [Penta1−measles]/Penta1×100%). The WHO recommends
that the coverage of both the Penta1 to Penta3 and Penta1 to
MCV1 dropout rates should be <10% so as to have better im-
munization coverage as well as reduced rates of morbidity and
mortality in children<5 y of age.28,29 It should be taken into con-
sideration that a dropout rate of >10% reflects underutilization
of immunization services. Initial utilization of an immunization
program was defined as the proportion of children who received
Penta1 vaccine during the past year in a region/district. The nu-
merator for this indicator is the number of children 12–23months
of age who received either BCG or Penta1 vaccine and the de-
nominator is the number of children 12–23months of age eligible
for Penta1 vaccination. Continuous utilization of an immunization
programwas defined as the proportion of children 12–23months
of age who received a Penta3 vaccine during the past year in a
region/district. This indicator uses the number of children who re-
ceived Penta 3 vaccine as the numerator and the number of chil-
dren 12–23months of agewho are eligible for Penta3 vaccination
as the denominator. Adequate immunization coverage was de-
fined as the percentage of children ages 12–23monthswhowere
immunized with MR1 during the past year in a region/district.
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Figure 2. Trends in immunization coverage between 2004 and 2016.
12–23 months of age who received an MR1 vaccine by the num-
ber of children 12–23 months of age who were eligible for MR1
vaccination. FVCwas defined as children ages 12–23monthswho
received BCG, OPV3, Penta3, PCV3, RV2 and MCV1 vaccines. The
number of children fully vaccinated by 12–23 months according
to the vaccination calendar timeline is the numerator and the
number of children<12 y of age eligible for full vaccination is the
denominator.
Control variables
The control variables used in the present study included the year
in which the survey was carried out and the geographical region.
To establish a trend in immunization coverage, a 15-y period was
sampled (the years included 2004, 2010 and 2015–2016). The
geographical region (northern, central and southern) was used as
a proxy for administrative divisions in Malawi. The geographical
region was chosen to establish the most underperforming area
for policy changes.
Statistical analysis
Data were analysed using SAS software version 9.4 (SAS Insti-
tute, Cary, NC, USA) and Stata version 15 (StataCorp, College Sta-
tion, TX, USA). All analyses were performed separately for 2004,
2010 and 2015–2016. Data were presented as frequency and
percentage and, where necessary, data were presented in the
form of charts. Using Pearson’s χ2, the bivariate analysis was
performed to test the differences in distribution between groups
(Penta1 vs Penta3, Penta1 vs MCV1, initial utilization [yes/no],
continued utilization [yes/no], adequate coverage [yes/no] and
FVC [yes/no]). The multivariable analyses were conducted using
logistic regression to examine the magnitude of those unimmu-
nized with Penta3 and MCV1. The results of logistic regression
were presented as the adjusted odds ratio (aOR) with the corre-
sponding 95% confidence interval (CI). The statistical significance
was considered when p-values were <0.05.
Figure 3. Unvaccinated children with Penta 3 and MCV1.
Results
Immunization coverage
Immunization coverages for various antigens are presented
in Figure 2. In all three cohort years, immunization coverage was
the highest for BCG antigens (92% in 2004, 98% in 2010 and 98%
in 2015–2016) and lowest for OPV antigens (80% in 2004, 89% in
2010 and 83% in 2015–2016). The coverages of Penta3 andMCV1
were <90% in 2004. The other vaccination coverages were 92%
for Penta3 in 2010 and 93% for Penta3 in 2015. Furthermore, the
coverages for PCV3 and RV2 in 2015 were 90% and 92%, respec-
tively, while the coverages for MCV1 antigen in 2010 and 2015
were 93% and 91%, respectively.
Penta3 and MCV1 unimmunized children
Figure 3 displays the number of unimmunized children with
Penta3 and MCV1 between 2004 and 2015. The highest numbers
of unimmunized children were observed in 2004 and lowest in
2010. As seen in the figure, 264 children and 347 children were
unimmunized with Penta3 and MCV1 in 2004, respectively. Ad-
ditionally, 140 and 201 children were unimmunized with Penta3
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Table 2. Dropout rate in immunization coverage using DPT1–Penta1 and DPT3–Penta3
Year Infants vaccinated Penta1, n Infants vaccinated Penta3, n Difference (Penta1−Penta3), n Dropout rate (%) p-Value
2004 2101 1837 264 12.6 <0.001
2010 3712 3585 127 3.4 <0.001
2015–2016 3134 2994 140 4.5 <0.001
Table 3. Dropout rate in immunization coverage using DPT1–Penta1 and MCV1–MR1
Year Infants vaccinated Penta1, n Infants vaccinated MCV1, n Difference (Penta1−MCV1), n Dropout rate (%) p-Value
2004 2101 1754 347 16.5 <0.001
2010 3712 3531 181 4.9 <0.001
2015–2016 3134 2933 201 6.4 <0.001
Figure 4. Bottlenecks in the delivery of immunization services.
Penta3 and MCV1 dropout rates
Tables 2 and 3 present dropout rates for Penta3 and MCV1. The
dropout rates for both antigens were significantly>10% in 2004,
but with a U shape. In 2004 the Penta3 dropout rate was 12.6%,
in 2010 the dropout rate decreased significantly to 3.4% and in
2015–2016 the dropout rate increased slightly. Similarly in 2004
the MCV1 dropout rate was 16.5%, however, the dropout rate de-
creased significantly to about 5% in 2010 and slightly increased
in 2015–2016. The dropout rates in 2004 were higher than the
10.0% cut-off point recommended by the WHO.
Effective immunization coverage
The results for FVC showed an upside-down U-shape pattern in
all the indicators (initial utilization, Penta1; continuous utilization,
Penta3; adequate coverage, MCV1; and full vaccination coverage)
(Figure 4). The coverage for Penta1was 95% in 2004, 98% in 2010
and 97% in 2015–2016, while FVC was 65% in 2004, 84% in 2010
and 73% in 2015–2016.
χ2 results by geographical region
Table 4 shows the results of the bivariate analysis of effective
immunization coverage by geographical region. In 2004, signif-
icantly high coverage of Penta1 (97.2%), Penta3 (89.7%), MCV1
(83.33%) and FVC (70.6) was observed in the northern region.
In 2010, significantly high coverage of Penta1 (98.4%), Penta3
(95.9%), MCV1 (94.51%) and FVC (85.58%) was observed in the
northern region. In 2015–2016, significantly high coverage of
Penta1 (98.2%) and FVC (75.0%) was observed in the northern
region.
Logistic regression results
Tables 5 and 6 show the magnitude of being unimmunized with
Penta3 and MCV1. In Table 5, after adjusting for geographical re-
gion, compared with children who were immunized with Penta1,
those with Penta3 were 74% (aOR 0.26 [95% CI 0.21 to 0.32])
less likely to be immunized in 2004. Compared with children with
Penta1 immunization, those with Penta3 were 60% (aOR 0.40
[95% CI 0.31 to 0.51]) less likely to be immunized in 2010. Ad-
ditionally, children in 2015–2016 were 62% (aOR 0.29 [95% CI
0.23 to 0.48]) less likely to be immunized with Penta3 compared
with Penta1. In Table 6, children were 81% less likely to be immu-
nized with MCV1 (aOR 0.19 [95% 0.16 to 0.24]) in 2004 compared
with childrenwhowere immunizedwith Penta1. In 2010, children
were 69% (aOR 0.31 [95% CI 0.25 to 0.40]) less likely to be immu-
nized with MCV1 compared with Penta1. Further, in 2015–2016,
children were 71% (aOR 0.29 [95% CI 0.23 to 0.37]) less likely to
be immunized with MCV1 compared with Penta1.
Discussion
Health inequalities occur when health services are not being ac-
cessed or utilized by a certain portion of the population (based
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Table 4. Bivariate analysis of the geographical region variation in effective immunization coverage
Vaccine Region 2004 2010 2015–16
No, n (%) Yes, n (%) p-Value No, n (%) Yes, n (%) p-Value No, n (%) Yes, n (%) p-Value
Penta1 <0.0001 0.0017 0.0016
North 7 (2.8) 245 (97.2) 14 (2.1) 667 (97.9) 11 (1.8) 588 (98.2)
Central 68 (8.1) 777 (91.9) 45 (3.6) 1217 (96.4) 21 (1.8) 1111 (98.2)
Southern 35 (3.1) 1079 (96.9) 30 (1.61) 1828 (98.4) 59 (3.9) 1435 (96.1)
Penta3 <0.0001 <0.001 0.5618
North 26 (10.2) 226 (89.8) 34 (5.0) 647 (95.0) 38 (6.3) 561 (93.7)
Central 190 (22.5) 655 (77.5) 105 (8.3) 1157 (91.7) 79 (7.0) 1053 (93.0)
Southern 158 (14.2) 956 (85.8) 17 (4.1) 1781 (95.9) 114 (7.1) 1380 (92.9)
MCV1 0.0002 <0.001 0.7056
North 42 (16.7) 210 (83.3) 45 (6.6) 636 (93.4) 56 (9.4) 543 (90.6)
Central 213 (25.2) 632 (74.8) 123 (9.8) 1139 (90.2) 96 (8.5) 1036 (91.5)
Southern 202 (18.1) 912 (81.9) 102 (5.5) 1756 (94.5) 140 (9.4) 1354 (90.6)
FVC <0.0001 <0.001 0.0002
North 74 (29.4) 178 (70.6) 98 (14.4) 583 (85.6) 150 (25.0) 449 (75.0)
Central 348 (41.2) 497 (58.8) 262 (20.8) 1000 (79.2) 316 (27.9) 816 (72.1)
Southern 347 (31.2) 767 (68.2) 268 (14.4) 1590 (85.6) 418 (27.9) 1076 (72.1)
Table 5. Logistic regression results for Penta
Year Infants vaccinated (Penta1) Infants vaccinated (Penta3) Logistic regression*
No, n (%) Yes, n (%) No, n (%) Yes, n (%) aOR (95% CI) p-Value
2004 110 (5.0) 2101 (95.0) 374 (16.9) 1837 (83.1) 0.26 (0.21 to 0.32) <0.001
2010 89 (2.3) 3712 (97.7) 216 (5.7) 3585 (94.3) 0.40 (0.31 to 0.51) <0.001
2015–2016 91 (2.2) 3134 (97.8) 231 (7.2) 2994 (92.8) 0.38 (0.29 to 0.48) <0.001
*Adjusted for geographical region.
Table 6. Logistic regression results for MCV1
Year Infants vaccinated (Penta1) Infants vaccinated (MCV1) Logistic Regression*
No, n (%) Yes, n (%) No, n (%) Yes, n (%) aOR (95% CI) p-Value
2004 110 (5.0) 2101 (95.0) 475 (20.7) 1754 (79.3) 0.19 (0.16 to 0.24) <0.001
2010 89 (2.3) 3712 (97.7) 270 (7.1) 3531 (92.9) 0.31 (0.25 to 0.40) <0.001
2015–16 91 (2.82) 3134 (97.8) 292 (9.1) 2933 (90.9) 0.29 (0.23 to 0.37) <0.001
*Adjusted for geographical region.
geographical location). These inequalities can result from a lack
of resources required to meet the needs of vulnerable popula-
tions. Immunization is a process whereby an individual is made
immune or resistant to an infectious disease, typically by the ad-
ministration of a vaccine.30 Immunization can be delivered suc-
cessfully through outreach clinics and does not require anymajor
lifestyle changes. Hence it is accessible to even themost hard-to-
reach and vulnerable populations.30
The overarching aim of the present study was to examine the
effective immunization coverage, immunization dropout rate and
equity gaps among children ages 12–23 months in Malawi. The
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for most of the antigens, while the full immunization status was
estimated at 65–73% between 2004 and 2015–2016. The high-
est coverage was observed for BCG and the lowest for OPV1. The
BNA revealed that initial utilization of immunization was high
(Penta1 coverage) in all cohort years. Regarding continuous uti-
lization, the BNA revealed that over the 15 years the coverage
of Penta3 has improved, with 90% coverage in 2010 and 2015–
2016. Similar patterns were observed in immunization services
for MCV1.
The BNA revealed that despite the high coverages of various
antigens, the quality of immunization in Malawi (equity gaps) is
lagging. This is reflected in the low prevalence of FVC across the
years. This study revealed that across all the cohort years, chil-
dren were less likely to be immunized with Penta3 and MCV1,
which shows that a certain portion of parents have difficulties in
getting to (accessing) the immunization services for subsequent
doses or parents are not utilizing the health services (underuti-
lization of services). However, Penta1 coveragewas high, showing
that the availability and initial utilization of immunization services
is satisfactory in Malawi.
The dropout rate is assessed as the number of Penta1 and
Penta3 or Penta1 and MCV1 vaccines given to a child over 1 y. Ac-
cording to the WHO, a dropout rate of >10% is considered to be
undesirable and shows that a certain health facility has utilization
constraints.31 In this study, the dropout rates of Penta3 andMCV1
were significantly >10% in 2004 and <10% in 2010 and 2015–
2016. A low dropout rate is indicative of good utilization and
therefore of good service quality. Similarly, more children were
unimmunized with Penta3 and MCV1 in 2004. However, both
dropout rates and unimmunized status had U-shaped patterns,
indicating that immunization service in Malawi has been deteri-
orating in recent years. The possible causes of low immunization
uptake and high dropout rates vary across countries/regions, but
most countries in sub-Saharan Africa share similar root causes.
Themost common reasons for poor immunization are service or-
ganization problems, staffing problems and data collection and
reporting problems.32
We could not explicitly determine the reasons for the high
dropout rate and poor effective immunization coverage due to
the absence of data. However, previous research and informa-
tion fromhealth facilities has attributed the gaps in immunization
to immediate and underlying causes. Immediate causes include
cancellation of scheduled immunization sessions, vaccine being
out of stock at the health centre, inadequate supportive super-
vision and performance feedback to the health centre and poor
documentation and record keeping for immunization services.33
Also, health surveillance assistants (HSAs) have frequently re-
ported that a lack of clarity about the denominator of the data
used creates lots of missing values and that many hard-to-reach
communities are underserved by village clinics or outreach ser-
vices, thus putting women and children at risk of not accessing
the service as underlying causes of immunization inequalities.34
In line with previous research,7,14 the current study found that
full immunization coverage was below the 90% target set by the
WHO. An analysis of the effects of individual and community-
level factors on childhood immunization in Malawi indicated that
women’s education (especially those with no formal education),
women with either one antenatal visit or none, women with
no immunization card, women from the poorest households,
womenwith three andmore children,women from the central re-
gion and women from communities where distance to the near-
est health facilitywas perceived as a big problemwere reported to
have reduced odds of achieving full immunization coverage.7,14
In Mozambique it was reported that accessibility to vaccination
sites, no schooling of mothers and children born at home or out-
side were the reasons for incomplete vaccination.35 Additionally,
being born at a health institution, a higher level of maternal edu-
cation, media exposure, region of residence and residing in com-
munities possessing greater maternal antenatal care utilization
were positively associated with full childhood immunization in
Ethiopia.36
Limitations
The results of this study should be interpreted with caution. First,
a cross-sectional study design cannot be used to infer causal-
ity because a temporal sequence cannot be established. Second,
we used secondary data whose population estimates were ob-
tained from the2018Malawi Population andHousing Census con-
ducted by the National Statistical Office (NSO), thus the denom-
inator obtained from the NSO may differ from the head count
collected by the HSAs. Third, information on immunization was
collected from vaccination cards, thus our results are subject to
recall bias, as the respondents who did not have health cards
were asked to recall administered vaccines (2004: vaccine from
vaccination card, booklet or other home-based record, 57.43%;
vaccine frommother’s report, 7.0%; 2010: vaccine from vaccina-
tion card, booklet or other home-based record, 74.3%; vaccine
from mother’s report, 6.6%; 2015–2016: vaccine from vaccina-
tion card, booklet or other home-based record, 69%; vaccine from
mother’s report, 6.8%). Lastly, the datasets did not record any
information on unavailability of vaccines due to stockouts, ac-
cess to services, lack of adequate vaccine supply and inconsistent
scheduling of vaccination supply.
Recommendations
There is a need for intensified engagement with communities
through the Reaching Every Child approach so that children are
fully immunized. There is a need for health education and ori-
entation of service providers. In addition, immunization registers
and data quality should be investigated and dealt with accord-
ingly. Further research at health facilities is needed to validate the
results of the current study and to determine which health facili-
ties are underperforming. Finally, there is a need to introduce an
electronic immunization register in Malawi to facilitate the mon-
itoring of individual immunization schedules and the storage of
individual immunization histories. This may help to enhance the
performance of the EPI in terms of coverage, efficiency and ef-
fectiveness.
Conclusions
Fully immunized status over the 15 y of childhood has been lag-
ging, but immunization coverages for most of antigens are high
and the dropout rate over the last 10 y is lower than the WHO’s
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immunization services was satisfactory but continued utilization
and adequate coverage of immunization services had irregular
patterns. These results should help the Malawi EPI to address dis-
parities that are occurring in immunization services. There is a
need for further studies to establish the reasons for the lack of
full immunization coverage in Malawi.
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